Published in Hepatitis Weekly, September 6th, 1999
Researcher Z. Ben-Ari and colleagues from Petah Tiqva's Rabin Medical Center further found that resistance to lamivudine can be linked to liver fibrosis and necroinflammation.
Orthotopic liver transplantation (OLT) in patients with hepatitis B virus (HBV) infection is known to be associated with a high recurrence rate and poor prognosis.
Lamivudine, a nucleoside analogue, is a potent inhibitor of HBV replication, but it is associated with a 14-39 percent rate of resistance.
...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (1999-09-06)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.